Lv6
2180 积分 2020-06-30 加入
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
9天前
已完结
Interleukin 6 Receptor Blockade for Relapse Prevention in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease
10天前
已完结
Future treatments for myelin oligodendrocyte glycoprotein antibody-associated disease: the clinical trial landscape
10天前
已完结
Satralizumab could reduce relapse risk in people with MOGAD
11天前
已完结
Consensus Recommendations for the Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD): The MENACTRIMS Guidelines
11天前
已完结
Comparative efficacy of rituximab versus azathioprine in the treatment of MOG antibody-associated disease (MOGAD)
11天前
已完结
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Practical recommendations for diagnosis and management
11天前
已完结
NMOSD and MOGAD: Updates on diagnostic criteria
11天前
已完结
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): Mechanisms, Syndromes, and Management
11天前
已完结
Therapeutic updates in NMOSD and MOGAD: From present practice to future promise
11天前
已完结
皖公网安备34019202002308
